The Ehlers-Danlos syndrome and regional anesthesia

Completed

• Conditions: Ehlers-Danlos syndrome; mesenchymose; 10028396; 10010761; 10014982

• Registration Number: NL-OMON31537
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

For EDS patients
- People with all types of the Ehlers-Danlos Syndrome except type IV (the vascular type), proven by a geneticist or a comparably qualified person
- 18 to 65 years old
- Infomed consent;For the control group
- All subjects are matched with a patient from the EDS group for age and sex

Exclusion Criteria

For EDS patients
- EDS type IV (vascular type)
- No informed consent
- Younger than 18 or older than 65 years old
- Co-existing disease which increases the risk for regional anesthesia, this according to prudent daily clinical practice in the OR
- Hereditary or acquired (including drug induced) bleeding disorders
- Periferal mononeuropathy, polyneuropathy, Multiple Sclerosis or other relevant neurologic disorders;Control group
- EDS or direct family with EDS because of the possibility of undiagnosed EDS in the subject
- No informed consent
- Younger than 18 or older than 65 years old
- Co-existing disease which increases the risk for regional anesthesia, this according to prudent daily clinical practice in the OR
- Hereditary or acquired (including drug induced) bleeding disorders
- Periferal mononeuropathy, polyneuropathy, Multiple Sclerosis or other relevant neurologic disorders

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Analgesia in the region of the ulnar nerve within 60 minutes after application<br /><br>of an ulnar nerve block. This will be demonstrated by stimuli from a<br /><br>neurostimulator above 20 mA which will not be regarded as painful in case of an<br /><br>adequate block. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Analgesia from the subcutanous injections and the topical application of EMLA<br /><br>cream<br /><br>Time of onset of analgesia<br /><br>Time of end of analgesia<br /><br>Duration of analgesia</p><br>